Literature DB >> 2107194

Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer.

H Mori1, T Hanabayashi, Y Yamada, T Tamaya.   

Abstract

The interferon-gamma (IFN-gamma) productivity of peripheral blood mononuclear cells (PBMCs) was examined in 30 patients with uterine cervical cancer. The patients under 50 years of age had decreased IFN-gamma production compared with the age-matched controls. The IFN-gamma productivity in the patients over 50 years of age was decreased as well as in the age-matched controls. The proportion of monocytes in PBMCs did not correlate with the IFN-gamma productivity. The prostaglandin E2 (PGE2) productivity of PBMCs increased with the progress of cancer. PGE2 inhibited the IFN-gamma production by PBMCs, and the sensitivity of PBMCs to PGE2 was increased in the patients and controls over 60 years of age. The addition of indomethacin resulted in an increase in IFN-gamma production by PBMCs. These results suggest that the increased production of PGE2 and/or increased sensitivity to PGE2 are responsible for the decreased IFN-gamma production in patients with cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107194     DOI: 10.1007/bf00917497

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  19 in total

1.  Regulation of natural killer cytotoxicity by Escherichia coli-derived human interferon gamma.

Authors:  C D Platsoucas
Journal:  Scand J Immunol       Date:  1986-07       Impact factor: 3.487

2.  Immune interferon induction by T-cell mitogens involves different T-cell subpopulations.

Authors:  D L Archer; B G Smith; J T Ulrich; H M Johnson
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

3.  Cellular immunity in squamous cell carcinoma of the uterine cervix.

Authors:  S Levy; S Kopersztych; C C Musatti; J S Souen; C A Salvatore; N F Mendes
Journal:  Am J Obstet Gynecol       Date:  1978-01-15       Impact factor: 8.661

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

6.  Functional identity between murine gamma interferon and macrophage activating factor.

Authors:  R M Schultz; W J Kleinschmidt
Journal:  Nature       Date:  1983 Sep 15-21       Impact factor: 49.962

7.  Adjuvant immunotherapy of carcinoma colli with levamisole. Prevention of immunological depression following surgical therapy and radiotherapy.

Authors:  S Shiraki; H Mori; N Kadomoto; T Nakano; Y Yamada; K Noda
Journal:  Int J Immunopharmacol       Date:  1982

8.  Interleukin 2 regulates immune interferon (IFN gamma) production by normal and suppressor cell cultures.

Authors:  B A Torres; W L Farrar; H M Johnson
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

9.  Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

Authors:  J S Goodwin; R P Messner; G T Peake
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

10.  Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages.

Authors:  J I Kurland; R Bockman
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  5 in total

1.  New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer.

Authors:  Valeska B Guzman; Anatoly Yambartsev; Amador Goncalves-Primo; Ismael D C G Silva; Carmen R N Carvalho; Julisa C L Ribalta; Luiz Ricardo Goulart; Natalia Shulzhenko; Maria Gerbase-Delima; Andrey Morgun
Journal:  Hum Mol Genet       Date:  2008-03-12       Impact factor: 6.150

2.  Production of interferons and change of the lymphocyte subpopulation phenotype in peripheral blood at cervical papillomavirus infection.

Authors:  L Lazarenko; M Spivak; V Lakatosh; L Kryvokhatska; O Mikhailenko; A Rudenko; L Tkáciková; I Mikula
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

3.  Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues.

Authors:  M Ogino; H Hisatomi; M Murata; M Hanazono
Journal:  Jpn J Cancer Res       Date:  1999-07

4.  Effects of Perioperative Dexmedetomidine on Immunomodulation in Uterine Cancer Surgery: A Randomized, Controlled Trial.

Authors:  Jin Sun Cho; Kieun Seon; Min-Yu Kim; Sang Wun Kim; Young Chul Yoo
Journal:  Front Oncol       Date:  2021-11-16       Impact factor: 6.244

5.  Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls.

Authors:  Aagje G Bais; Ilse Beckmann; Patricia C Ewing; Marinus J C Eijkemans; Chris J L M Meijer; Peter J F Snijders; Theo J M Helmerhorst
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.